|Recruiting||Acute Myeloid Leukemia
This pilot clinical trial studies chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or advanced myelodysplastic syndrome. Patients receiving chemotherapy as an outpatient may have improved quality of life and less expense than patients receiving chemotherapy as an inpatient.
- Signed written informed consent
- Newly diagnosed AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in marrow or blood)
- Treatment-related mortality (TRM) score < 3.91 corresponding to a TRM rate of 1% when chemotherapy of similar intensity as proposed here is administered to inpatients
- White blood cell (WBC) count =< 10,000
- Fibrinogen > 200
- Afebrile with a clear chest x-ray and no signs of active viral, bacterial, or fungal infection
- Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater by multiple gated acquisition (MUGA) or echocardiogram
- No ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
- Patient must have an outpatient caregiver available
- Patient must live within 30 minutes of the Seattle Cancer Care Alliance during outpatient treatment
- Patient must be willing to return to the Seattle Cancer Care Alliance for outpatient follow-up once outpatient treatment is completed
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.